Peipei Zhang1, Xiaojing Liu1, Aili Guo1, Jing Xiong1, Yu Fu2, Kaifang Zou3. 1. Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China. 2. Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China. future-yu@163.com. 3. Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, Hubei, China. zoukaifang524@gmail.com.
Abstract
BACKGROUND: B cell-activating factor (BAFF) has been proposed to be a regulator of B cell and T cell immune responses and be associated with inflammatory processes in autoimmunity and B cell malignancies. No study has reported the role of BAFF in inflammatory bowel disease (IBD). AIMS: The purpose of this study was to investigate expression and concentrations of BAFF in IBD and determine its value to discriminate patients with IBD. METHODS: Seventy-eight ulcerative colitis (UC) patients, 37 Crohn's disease (CD) patients, 12 irritable bowel syndrome (IBS) patients and 44 healthy controls were recruited. We examined serum and faecal BAFF levels using enzyme-linked immunosorbent assay. Intestinal BAFF expression was analysed in biopsies obtained from IBD patients. Intestinal mucosa localization of BAFF was conducted by immunofluorescence. RESULTS: The median (25th-75th percentile) serum BAFF concentration (pg/ml) was 1430 (1105-1624) in CD patients, 1472 (1018-1772) in UC patients and 977 (482-1345) in healthy controls. Serum BAFF was 64 % sensitive and 93 % specific for identifying active IBD from healthy controls. The BAFF expression was significantly increased in biopsy specimens from IBD patients. Fecal BAFF concentration was 369 (326-493) pg/ml in CD patients, 542 (358-1758) pg/ml in UC patients, 294 (287-299) pg/ml in IBS patients and 295 (284-309) pg/ml in healthy controls. Fecal BAFF was 90 % sensitive and 96 % specific for identifying active IBD from healthy controls and IBS patients. CONCLUSION: The novel association between BAFF and IBD seems to identify that BAFF might regulate the inflammatory process in these diseases and it appears to be a potential marker of IBD.
BACKGROUND:B cell-activating factor (BAFF) has been proposed to be a regulator of B cell and T cell immune responses and be associated with inflammatory processes in autoimmunity and B cell malignancies. No study has reported the role of BAFF in inflammatory bowel disease (IBD). AIMS: The purpose of this study was to investigate expression and concentrations of BAFF in IBD and determine its value to discriminate patients with IBD. METHODS: Seventy-eight ulcerative colitis (UC) patients, 37 Crohn's disease (CD) patients, 12 irritable bowel syndrome (IBS) patients and 44 healthy controls were recruited. We examined serum and faecal BAFF levels using enzyme-linked immunosorbent assay. Intestinal BAFF expression was analysed in biopsies obtained from IBD patients. Intestinal mucosa localization of BAFF was conducted by immunofluorescence. RESULTS: The median (25th-75th percentile) serum BAFF concentration (pg/ml) was 1430 (1105-1624) in CDpatients, 1472 (1018-1772) in UC patients and 977 (482-1345) in healthy controls. Serum BAFF was 64 % sensitive and 93 % specific for identifying active IBD from healthy controls. The BAFF expression was significantly increased in biopsy specimens from IBD patients. Fecal BAFF concentration was 369 (326-493) pg/ml in CDpatients, 542 (358-1758) pg/ml in UC patients, 294 (287-299) pg/ml in IBSpatients and 295 (284-309) pg/ml in healthy controls. Fecal BAFF was 90 % sensitive and 96 % specific for identifying active IBD from healthy controls and IBSpatients. CONCLUSION: The novel association between BAFF and IBD seems to identify that BAFF might regulate the inflammatory process in these diseases and it appears to be a potential marker of IBD.
Authors: W Reinisch; C Gasché; W Tillinger; J Wyatt; C Lichtenberger; M Willheim; C Dejaco; T Waldhör; S Bakos; H Vogelsang; A Gangl; H Lochs Journal: Am J Gastroenterol Date: 1999-08 Impact factor: 10.864
Authors: Viktor Roschke; Svetlana Sosnovtseva; Christopher D Ward; June S Hong; Rodger Smith; Vivian Albert; William Stohl; Kevin P Baker; Stephen Ullrich; Bernardetta Nardelli; David M Hilbert; Thi-Sau Migone Journal: J Immunol Date: 2002-10-15 Impact factor: 5.422
Authors: Anne J Novak; Jaime R Darce; Bonnie K Arendt; Brandon Harder; Kathy Henderson; Wayne Kindsvogel; Jane A Gross; Philip R Greipp; Diane F Jelinek Journal: Blood Date: 2003-09-25 Impact factor: 22.113
Authors: Qunrui Ye; Liqing Wang; Andrew D Wells; Ran Tao; Rongxiang Han; Anne Davidson; Martin L Scott; Wayne W Hancock Journal: Eur J Immunol Date: 2004-10 Impact factor: 5.532
Authors: Ansu Mammen Noronha; YanMei Liang; Jeremy T Hetzel; Hatice Hasturk; Alpdogan Kantarci; Arthur Stucchi; Yue Zhang; Barbara S Nikolajczyk; Francis A Farraye; Lisa M Ganley-Leal Journal: J Leukoc Biol Date: 2009-07-09 Impact factor: 4.962
Authors: Malgorzata Matusiewicz; Katarzyna Neubauer; Paulina Lewandowska; Andrzej Gamian; Malgorzata Krzystek-Korpacka Journal: Biomed Res Int Date: 2017-10-31 Impact factor: 3.411
Authors: Angela Zou; Kerry Nadeau; Pauline W Wang; Jee Yeon Lee; David S Guttman; Shayan Sharif; Doug R Korver; John H Brumell; John Parkinson Journal: BMC Genet Date: 2020-01-17 Impact factor: 2.797